Lynch Syndrome and understanding your options
People with Lynch Syndrome are at a higher risk than the general population of developing some cancers. Identifying people who have Lynch Syndrome can have important benefits, including prevention of cancer, spotting it early and helping doctors decide on the best treatment for people who do develop cancer.
This booklet aims to help you understand more about the syndrome, what your options are…
This provides the blueprint for the necessary development of hereditary cancer services in Ireland.
While the cause of most cancers is unknown, about one in 10 cancers are caused by changes in genes that can be passed down in families.
The lifetime risk of developing colorectal cancer is up to 52% for people with a gene mutation associated with Lynch syndrome, compared to about 4% for the general population.
These people also tend to get cancer at an earlier-than-average age. It’s estimated that less than 10% are aware of their status.
NCCN expanding genetic testing to “Any Lynch related cancer” instead of colon and endometrial cancer as one of the testing criteria
Individuals with Lynch syndrome are at increased risk for multiple cancer types (common ones shown here). Note: MLH1 has the highest pancreatic cancer risk, MSH2 has the highest urothelial & prostate cancer risk, & PMS2 risks are mainly CRC & EC.
Be aware of gene changes and cancer in your family and take part in screening to reduce your risk of cancer.
Lynch Syndrome is an inherited condition that increases your risk of developing some cancers, including bowel, womb and ovarian cancer. We have developed a guide to run through everything you need to know about Lynch.
This guide has been made with input from experts, people with Lynch Syndrome and our Ask Eve nurses to provide you with all the information you need when offered testing for, or navigating a diagnosis of, Lynch Syndrome.
We also have an Easy Read guide to Lynch Syndrome, which you can download here
Lynch Syndrome
What is this study about?
The IMPACT trial is an international study looking at how well PSA (prostate-specific antigen) screening for prostate cancer works for people with inherited mutations. This report shared early results of screening in people with Lynch syndrome.
Initial results from the IMPACT trial show that PSA testing to screen for prostate cancer in people with Lynch syndrome can detect aggressive early prostate cancers. These findings support the use of PSA screening in men with Lynch syndrome, particularly men with an inherited mutation in an MSH2 or MSH6 gene.
https://www.facingourrisk.org/XRAY/prostate-cancer-screening-benefits-for-Lynch-syndrome
Patient webinar for people with advanced prostate cancer, their caregivers, and their families.
Experts provide information and answer questions about advanced prostate cancer to help patients and caregivers compare, discuss, and select treatment options with their doctor.
NCCN Patient Webinar : https://youtu.be/OgqnEyEdzh0
Lynch Syndrome Ireland 